Oculopharyngeal muscle dystrophy: Fine structure and mRNA expression levels of PABPN1

Clinical Neuropathology

Volumn 30, Issue 3, 2011, Pages 94-103

  Schroder J M ^a   Klossok, T ^a   Weis, J ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Fine structural phenotype; GCG and GCA repeats; Genotype; Oculopharyngeal muscular dystrophy (PMD); PABPN1 gene

Indexed keywords

DNA; MESSENGER RNA; TRINUCLEOTIDE; POLYADENYLIC ACID BINDING PROTEIN;

ADULT; AGED; ARTICLE; CELL NUCLEUS INCLUSION BODY; CELL SIZE; CHROMOSOME 14Q; CLINICAL ARTICLE; EXON; FEMALE; FROZEN SECTION; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE INSERTION; GENE STRUCTURE; GENETIC CORRELATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN TISSUE; MALE; MUSCLE BIOPSY; MUSCLE WEAKNESS; MUTATIONAL ANALYSIS; OCULOPHARYNGEAL MUSCULAR DYSTROPHY; PABPN1 GENE; PRIORITY JOURNAL; TRINUCLEOTIDE REPEAT; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTRANUCLEAR INCLUSION BODIES; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MIDDLE AGED; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, OCULOPHARYNGEAL; MUTATION; POLY(A)-BINDING PROTEIN II; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 79960120588     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.5414/NPP30094     Document Type: Article

References (53)

1. Arenas J, Huertas RA, Campos Y, Cabello A, Gutierrez E, Bautista J, Segura D. Oculopharyngeal muscular dystrophy and mitochondrial abnormalities. Muscle Nerve. 1992; 15: 1055-1056.
2. Askanas V, Serdaroglu P, Engel WK, Alvarez RB. Immunolocalization of ubiquitin in muscle biopsies of patients with inclusion body myositis and oculopharyngeal muscular dystrophy. Neurosci Lett. 1991; 130: 73-76.
3. Blumen SC, Bouchard JP, Brais B, Carasso RL, Paleacu D, Drory VE, Chantal S, Blumen N, Braverman I. Cognitive impairment and reduced life span of oculopharyngeal muscular dystrophy homozygotes. Neurology. 2009; 73: 596-601.
4. Blumen SC, Korczyn AD, Lavoie H, Medynski S, Chapman J, Asherov A, Nisipeanu P, Inzelberg R, Carasso RL, Bouchard JP, Tome FM, Rouleau GA, Brais B. Oculopharyngeal MD among Bukhara Jews is due to a founder (GCG)9 mutation in the PABP2 gene. Neurology. 2000; 55: 1267-1270.
5. Boukriche Y, Maisonobe T, Masson C. Neurogenic involvement in a case of oculopharyngeal muscular dystrophy. Muscle Nerve. 2002; 25: 98-101.
6. Brais B. Oculopharyngeal muscular dystrophy: a late-onset polyalanine disease. Cytogenet Genome Res. 2003; 100: 252-260.
7. Brais B. Oculopharyngeal muscular dystrophy: a polyalanine myopathy. Curr Neurol Neurosci Rep. 2009; 9: 76-82.
8. Brais B, Bouchard JP, Xie YG, Rochefort DL, Chretien N, Tome FM, Lafreniere RG, Rommens JM, Uyama E, Nohira O, Blumen S, Korczyn AD, Heutink P, Mathieu J, Duranceau A, Codere F, Fardeau M, Rouleau GA, Korcyn AD. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet. 1998; 18: 164-167.
9. Brais B, Xie YG, Sanson M, Morgan K, Weissenbach J, Korczyn AD, Blumen SC, Fardeau M, Tome FM, Bouchard JP et al. The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac alpha and beta myosin heavy chain genes on chromosome 14q11.2-q13. HumMol Genet. 1995; 4: 429-434.
10. Brunet G, Tome FM, Eymard B, Robert JM, Fardeau M. Genealogical study of oculopharyngeal muscular dystrophy in France. Neuromuscul Disord. 1997; 7 (Suppl): 34-37.
11. Calado A, Kutay U, Kuhn U, Wahle E, Carmo-Fonseca M. Deciphering the cellular pathway for transport of poly(A)-binding protein II. Rna. 2000; 6: 245-256.
12. Chen Z, Li Y, Krug RM. Influenza Avirus NS1 protein targets poly(A)-binding protein II of the cellular 3'-end processing machinery. Embo J. 1999; 18: 2273-2283.
13. Davies JE, Sarkar S, Rubinsztein DC. Wild-type PABPN1 is anti-apoptotic and reduces toxicity of the oculopharyngeal muscular dystrophy mutation. Hum Mol Genet. 2008; 17: 1097-1108.
14. Fan X, Dion P, Laganiere J, Brais B, Rouleau GA. Oligomerization of polyalanine expanded PABPN1 facilitates nuclear protein aggregation that is associated with cell death. Hum Mol Genet. 2001; 10: 2341-2351.
15. Goas JY, Leroy JP, Mocquard Y, Rouhart F. Acase of mitochondrial myopathy in a family with oculo-pharyngeal myopathy. Rev Neurol (Paris). 1991; 147: 536-537.
16. Hardiman O, Halperin JJ, Farrell MA, Shapiro BE, Wray SH, Brown RH, Jr. Neuropathic findings in oculopharyngeal muscular dystrophy. A report of seven cases and a review of the literature. Arch Neurol. 1993; 50: 481-488.
17. Hill ME, Creed GA, McMullan TF, Tyers AG, Hilton-Jones D, Robinson DO, Hammans SR. Oculopharyngeal muscular dystrophy: phenotypic and genotypic studies in a UK population. Brain. 2001; 124: 522-526.
18. Julien J, Vital C, Vallat JM, Vallat M, Le Blanc M. Oculopharyngeal muscular dystrophy. Acase with abnormal mitochondria and "fingerprint" inclusions. J Neurol Sci. 1974; 21: 165-169.
19. Kuhn U, Wahle E. Structure and function of poly(A) binding proteins. Biochim Biophys Acta. 2004; 1678: 67-84.
20. Kunst CB, Warren ST. Cryptic and polar variation of the fragile X repeat could result in predisposing normal alleles. Cell. 1994; 77: 853-861.
21. Lampe JB, Schäfer J, Gärtner HJ, Reichmann H. Proximal weakness and exercise-induced pain as initial symptom of oculopharyngeal muscular dystrophy. Nervenarzt. 2001; 72: 652-655.
22. Leclerc A, Tome FM, Fardeau M. Ubiquitin and beta-amyloid-protein in inclusion bodymyositis (IBM), familial IBM-like disorder and oculopharyngeal muscular dystrophy: an immunocytochemical study. Neuromuscul Disord. 1993; 3: 283-291.
23. Marsh EA, Robinson DO. Acase of rare recessive oculopharyngeal muscular dystrophy (OPMD) coexisting with hereditary neuropathy with liability to pressure palsies (HNPP). Clin Neurol Neurosurg. 2008; 110: 525-528.
24. Meyer S, Urbanke C, Wahle E. Equilibrium studies on the association of the nuclear poly(A) binding protein with poly(A) of different lengths. Biochemistry. 2002; 41: 6082-6089.
25. Mihaylova V, Muller T, Petrova I, Tournev I, Cherninkova S, Walter MC, Deschauer M. Unique PABPN1 gene mutation in a large Bulgarian family with OPMD. J Neurol. 2008; 255: 609-611.
26. Minami N, Ikezoe K, Kuroda H, Nakabayashi H, Satoyoshi E, Nonaka I. Oculopharyngodistal myopathy is genetically heterogeneous and most cases are distinct from oculopharyngealmuscular dystrophy. Neuromuscul Disord. 2001; 11: 699-702.
27. Müller T, Deschauer M, Kolbe-Fehr F, Zierz S. Genetic heterogeneity in 30 German patients with oculopharyngeal muscular dystrophy. J Neurol. 2006; 253: 892-895.
28. Myers RH, Marams KS. M.E.M. Huntington's disease. In: Wells RD, Warren ST (eds). Genetic Instabilities and Heriditary Neurological Diseases. San Diego: Academic Press; 1998. p. 301-323.
29. Nakamoto M, Nakano S, Kawashima S, Ihara M, Nishimura Y, Shinde A, Kakizuka A. Unequal crossing-over in unique PABP2 mutations in Japanese patients: a possible cause of oculopharyngealmuscular dystrophy. Arch Neurol. 2002; 59: 474-477.
30. Ohshima K, Wells RD. InVitro Synthesis of Triplet Repeat Sequences. In:Wells RD, Warren ST (eds). Genetic Instabilities and Heriditary Neurological Diseases. San Diego: Academic Press; 1998. p. 717-732.
31. Pauzner R, Blatt I, Mouallem M, Ben-David E, Farfel Z, Sadeh M. Mitochondrial abnormalities in oculopharyngeal muscular dystrophy. Muscle Nerve. 1991; 14: 947-952.
32. Porschke H, Kress W, Reichmann H, Goebel HH, Grimm T. Oculopharyngeal muscular dystrophy in a northern German family linked to chromosome 14q, and presenting carnitine deficiency. Neuromuscul Disord. 1997; 7 (Suppl): 57-62.
33. Pratt MF, Meyers PK. Oculopharyngeal muscular dystrophy: recent ultrastructural evidence for mitochondrial abnormalities. Laryngoscope. 1986; 96: 368-373.
34. Probst A, Tackmann W, Stoeckli HR, Jerusalem F, Ulrich J. Evidence for a chronic axonal atrophy in oculopharyngeal "muscular dystrophy". Acta Neuropathol (Berl). 1982; 57: 209-216.
35. Rankin J, Wyttenbach A, Rubinsztein DC. Intracellular green fluorescent protein-polyalanine aggregates are associated with cell death. Biochem J. 2000; 348: 15-19.
36. Rivera D, Mejia-Lopez H, Pompa-Mera EN, Villanueva-Mendoza C, Nava-Castaneda A, Garnica-Hayashi L, Cuevas-Covarrubias S, Zenteno JC. Two different PABPN1 expanded alleles in a Mexican population with oculopharyngeal muscular dystrophy arising from independent founder effects. Br J Ophthalmol. 2008; 92: 998-1002.
37. Robinson DO, Hammans SR, Read SP, Sillibourne J. Oculopharyngeal muscular dystrophy (OPMD): analysis of the PABPN1 gene expansion sequence in 86 patients reveals 13 different expansion types and further evidence for unequal recombination as the mutational mechanism. Hum Genet. 2005; 116: 267-271.
38. Robinson DO, Wills AJ, Hammans SR, Read SP, Sillibourne J. Oculopharyngeal muscular dystrophy: a point mutation which mimics the effect of the PABPN1 gene triplet repeat expansion mutation. J Med Genet. 2006; 43: 23.
39. Satoyoshi E, Kinoshita M. Oculopharyngodistal myopathy. Arch Neurol. 1977; 34: 89-92.
40. Scacheri PC, Garcia C, Hebert R, Hoffman EP. Unique PABP2 mutations in "Cajuns" suggest multiple founders of oculopharyngeal muscular dystrophy in populations with French ancestry. Am J Med Genet. 1999; 86: 477-481.
41. Schmitt HP, Krause KH. An autopsy study of a familial oculopharyngeal muscular dystrophy (OPMD) with distal spread and neurogenic involvement. Muscle Nerve. 1981; 4: 296-305.
42. Schober R, Kress W, Grahmann F, Kellermann S, Baum P, Gunzel S, Wagner A. Unusual triplet expansion associated with neurogenic changes in a family with oculopharyngeal muscular dystrophy. Neuropathology. 2001; 21: 45-52.
43. Schröder JM. Pathologie der Muskulatur. Berlin-Heidelberg-New York: Springer; 1982.
44. Schröder JM, Krabbe B, Weis J. Oculopharyngeal muscular dystrophy: clinical and morphological follow-up study reveals mitochondrial alterations and unique nuclear inclusions in a severe autosomal recessive type. Neuropathol Appl Neurobiol. 1995; 21: 68-73.
45. Taylor EW. Progressive vagus glossopharyngeal paralysis with ptosis: a contribution to the group of family diseases. J Nerv Ment Dis. 1915; 42: 129-139.
46. Tome FM, Chateau D, Helbling-Leclerc A, Fardeau M. Morphological changes in muscle fibers in oculopharyngeal muscular dystrophy. Neuromuscul Disord. 1997; 7 (Suppl): 63-69.
47. Tome FM, Fardeau M. Nuclear inclusions in oculopharyngeal dystrophy. Acta Neuropathol (Berl). 1980; 49: 85-87.
48. Uyama E, Uchino M, Chateau D, Tome FM. Autosomal recessive oculopharyngodistal myopathy in light of distal myopathy with rimmedvacuoles and oculopharyngeal muscular dystrophy. Neuromuscul Disord. 1998; 8: 119-125.
49. Van Der Sluijs BM, Hoefsloot LH, Padberg GW, Van Der Maarel SM, Van Engelen BG. Oculopharyngeal muscular dystrophy with limb girdle weakness as major complaint. J Neurol. 2003; 250: 1307-1312.
50. Van der Sluijs BM, van Engelen BG, Hoefsloot LH. Oculopharyngeal muscular dystrophy (OPMD) due to a small duplication in the PABPN1 gene. Hum Mutat. 2003; 21: 553.
51. Victor M, Hayes R, Adams RD. Oculopharyngeal muscular dystrophy. A familial disease of late life characterized by dysphagia and progressive ptosis of the evelids. N Engl J Med. 1962; 267: 1267-1272.
52. Warren ST. Polyalanine expansion in synpolydactyly might result from unequal crossing-over of HOXD13. Science. 1997; 275: 408-409.
53. Wells RD. Molecular basics of genetic instability of triplet repeats. J Biol Chem. 1996; 271: 2875-2878.